Tag Archive clinic

Gene that pushes normal pancreas cells to change shape identified

Dr. Brilliant no comments

Their findings, reported in Nature Communications, suggest that inhibiting the gene, protein kinase D1 (PKD1), and its protein could halt progression and spread of this form of pancreatic cancer, and possibly even reverse the transformation. “As soon as pancreatic cancer develops, it begins to spread, and PKD1 is key to both processes. Given this finding, we are busy developing a PKD1 inhibitor that we can test further,” says the study’s co-lead investigator, Peter Storz, Ph.D., a cancer researcher at Mayo Clinic…

Immune function marker does not predict benefit of trastuzumab in HER-2+ breast cancer patients — ScienceDaily

Dr. Expert no comments

And since trastuzumab, and not chemotherapy alone, is the standard of care for the HER2-positive sub-class of breast cancer, there is no need to test for these lymphocytes in HER2-positive patients in order to predict outcome, say researchers from Mayo Clinic in Florida. These findings, presented at the 2014 San Antonio Breast Cancer Symposium, don’t mean that immune function in this class of cancer isn’t important — just that it is likely more complicated than measuring the number of these lymphocytes, says the study’s lead author, Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center, and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. …

Investigational oral drug combo shows promise for newly diagnosed multiple myeloma

Dr. Expert no comments

“Ixazomib is an investigational, oral proteasome inhibitor with promising anti-myeloma effects and low rates of peripheral neuropathy,” says Shaji Kumar, M.D., a hematologist at Mayo Clinic and lead author of the study. “While it is well known that a combination of bortezomib, lenalidomide and dexamethasone is highly effective in treating newly diagnosed multiple myeloma, we wanted to study the safety, tolerability and activity of ixazomib in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma.” Dr. Kumar and colleagues enrolled 65 patients (15 to phase 1 and 50 to phase 2) between November 2010 and February 2012. …

First steps in formation of pancreatic cancer identified

Dr. Brilliant no comments

In an online issue of Cancer Discovery, the scientists described the molecular steps necessary for acinar cells in the pancreas — the cells that release digestive enzymes — to become precancerous lesions. …

Updated criteria for diagnosing multiple myeloma published by international research group

Dr. Expert no comments

“Our group, which includes more than 180 myeloma researchers worldwide, has updated the definition of multiple myeloma for diagnostic purposes to include validated biomarkers in addition to the current clinical symptoms used for diagnosis which include, elevated blood calcium levels, kidney failure, anemia and bone lesions,” said lead author S. Vincent Rajkumar, M.D. a hematologist at Mayo Clinic. …

Trastuzumab should remain as standard of care for HER2-positive breast cancer, trial suggests

Dr. Expert no comments

This study, being presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, reveals that when used as a single HER2-targeted therapy in addition to standard chemotherapy, trastuzumab offers a better outcome than does lapatinib (Tykerb), says Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. …

Most breast cancer patients who had healthy breast removed at peace with decision — ScienceDaily

Dr. Expert no comments

The study made a surprising finding: While most women were satisfied with their decision whether they followed it with breast reconstruction or not, patients who decided against reconstructive surgery were likelier to say they would choose to have both breasts removed again. …

Family conflicts, other non-physical worries before cancer surgery raise patients’ complication risk

Dr. Expert no comments

The findings are published in the Journal of Gastrointestinal Surgery. “We know that quality of life is a very complex thing, but we can now measure it and work with it almost like blood pressure,” says lead author Juliane Bingener, M.D., a gastroenterologic surgeon at Mayo Clinic in Rochester. “We can say, ‘This is good, this is in the normal range, but this one here, that is not good, and maybe we should do something.'” Quality of life as measured in the study is about more than happiness and how well people feel physically, Dr…

New tool aids stem cell engineering for medical research

Dr. Expert no comments

“This free platform has a broad range of uses for all types of cell-based investigations and can potentially offer help to people working on all types of cancer,” says Hu Li, Ph.D., investigator in the Mayo Clinic Center for Individualized Medicine and Department of Molecular Pharmacology & Experimental Therapeutics, and co-lead investigator in the two works. “CellNet will indicate how closely an engineered cell resembles the real counterpart and even suggests ways to adjust the engineering.” The network biology platform contains data on a wide range of cells and details on what is known about those cell types. Researchers say the platform can be applied to almost any study and allows users to refine the engineering process. In the long term, it should provide a reliable short cut to the early phases of drug development, individualized cancer therapies, and pharmacogenetics. …

Less radical procedures offer similar cancer control compared to surgery for kidney cancer patients

Dr. Expert no comments

Dr. Thompson says radical nephrectomy — surgical removal of the entire kidney — has historically been the standard of care for management of kidney cancer; however, partial nephrectomy — surgical removal of tumors from a kidney while sparing healthy tissue -has become increasingly more common because of its nephron-sparing benefits and similar cancer control…